MBX Biosciences, Inc. has made a significant addition to its leadership team by appointing Peter Radovich as a new director. This change, effective October 20, 2026, is intended to strengthen the company’s governance and strategic direction in the competitive pharmaceutical preparations industry.

The appointment was made upon the recommendation of the Nominating and Corporate Governance Committee of the Board. The Board has determined that Radovich meets the independence standards set by The Nasdaq Stock Market.

Radovich will serve as a Class I director until the company’s 2028 Annual Meeting of Stockholders. His role will continue until a successor is elected or he resigns, is removed, or passes away. This appointment brings the total number of directors on the Board to eight.

As part of his compensation package, Radovich will receive an initial award of a non-qualified stock option to purchase 18,200 shares of the company’s common stock, which will be granted on the date of his appointment. He will also receive cash compensation in accordance with MBX's Non-Employee Director Compensation Policy, which was last amended in March 2026.

Additionally, an indemnification agreement will be established with Radovich, similar to those used for the company’s other directors. The filing indicates that there are no arrangements or understandings between Radovich and any other parties regarding his selection as a director, nor are there any transactions that require disclosure under Item 404(a) of Regulation S-K.

Background

MBX Biosciences, Inc. operates in the pharmaceutical preparations sector, classified under SIC 2834. The company is publicly traded on the Nasdaq under the ticker symbol MBX. It is incorporated in Delaware and has its principal executive offices located in Carmel, Indiana.

What the Filing Says

The filing states, “Effective as of October 20, 2026, the board of directors... appointed Peter Radovich as a director of the Company.” It further details Radovich's compensation and the terms of his appointment.

Impact

This appointment may influence the company’s strategic direction and governance practices, potentially affecting shareholders and stakeholders in the pharmaceutical preparations industry.

What's Next

The filing does not say what happens next.